eGFRCystatin C, difference between eGFRCystatin C and eGFRCre and heart failure: Insight from the NHANES 2001–2002 and Mendelian randomization analysis
Zhiyu Gu , Rui Zhang , Weihong Chang , Hongxuan Fan , Zixuan Dou , Peng Liu , Aman Liu , Boda Zhou
{"title":"eGFRCystatin C, difference between eGFRCystatin C and eGFRCre and heart failure: Insight from the NHANES 2001–2002 and Mendelian randomization analysis","authors":"Zhiyu Gu , Rui Zhang , Weihong Chang , Hongxuan Fan , Zixuan Dou , Peng Liu , Aman Liu , Boda Zhou","doi":"10.1016/j.ijcrp.2024.200337","DOIUrl":null,"url":null,"abstract":"<div><h3>Aim</h3><div>Estimated glomerular filtration rate (eGFR) derived from Cystatin C (eGFR<sub>Cystatin C</sub>), and the difference between Cystatin C and creatinine based eGFR (eGFR<sub>diff</sub>) has been suggested to be associated with cardiovascular disease. However, the association between eGFR<sub>Cystatin C</sub>,eGFR<sub>diff</sub> and heart failure (HF) risk has not been elucidated in a relatively healthy cohort.</div></div><div><h3>Methods</h3><div>We used cohort study data from the NHANES 2001–2002. Mendelian randomization (MR) study used GWAS data from 437,846 European participants. The exposures are eGFR<sub>Cystatin C</sub> & eGFR<sub>diff</sub>, outcome is self reported heart failure. Weighted multivariable-adjusted logistic regression and Kaplan-Meier survival analysis was used in corhort study. Inverse variance weighted (IVW) was applied in MR study.</div></div><div><h3>Results</h3><div>The cohort study included 2155 participants. Importantly, we simplified eGFR<sub>diff</sub> classification into ≥0 and < 0, and found that eGFR<sub>diff</sub>≥0 was associated with 52 % reduction of HF risk (OR 0.48, [95 % CI, 0.29–0.80], p = 0.005). We also found that 1 ml/min/1.73 m<sup>2</sup> of eGFR<sub>Cystatin C</sub> had a significant negative association with HF after adjusting for covariates. Interestingly, we showed a non-linear association between eGFR<sub>Cystatin C</sub> and HF, eGFR<sub>diff</sub> and HF. In participants without know HF, during a median follow-up of 17.3 years, those in the low eGFR<sub>Cystatin C</sub> or low eGFR<sub>diff</sub> groups showed significantly poorer survival. Moreover, MR analysis found genetic predisposition to cystatin C was significantly associated with an increased risk of HF.</div></div><div><h3>Conclusion</h3><div>Both decreased eGFR<sub>Cystatin C</sub> and eGFR<sub>diff</sub> levels were associated with heart failure and poor survival, but the latter seems more obvious.</div></div>","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"23 ","pages":"Article 200337"},"PeriodicalIF":1.9000,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Cardiology Cardiovascular Risk and Prevention","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772487524001028","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0
Abstract
Aim
Estimated glomerular filtration rate (eGFR) derived from Cystatin C (eGFRCystatin C), and the difference between Cystatin C and creatinine based eGFR (eGFRdiff) has been suggested to be associated with cardiovascular disease. However, the association between eGFRCystatin C,eGFRdiff and heart failure (HF) risk has not been elucidated in a relatively healthy cohort.
Methods
We used cohort study data from the NHANES 2001–2002. Mendelian randomization (MR) study used GWAS data from 437,846 European participants. The exposures are eGFRCystatin C & eGFRdiff, outcome is self reported heart failure. Weighted multivariable-adjusted logistic regression and Kaplan-Meier survival analysis was used in corhort study. Inverse variance weighted (IVW) was applied in MR study.
Results
The cohort study included 2155 participants. Importantly, we simplified eGFRdiff classification into ≥0 and < 0, and found that eGFRdiff≥0 was associated with 52 % reduction of HF risk (OR 0.48, [95 % CI, 0.29–0.80], p = 0.005). We also found that 1 ml/min/1.73 m2 of eGFRCystatin C had a significant negative association with HF after adjusting for covariates. Interestingly, we showed a non-linear association between eGFRCystatin C and HF, eGFRdiff and HF. In participants without know HF, during a median follow-up of 17.3 years, those in the low eGFRCystatin C or low eGFRdiff groups showed significantly poorer survival. Moreover, MR analysis found genetic predisposition to cystatin C was significantly associated with an increased risk of HF.
Conclusion
Both decreased eGFRCystatin C and eGFRdiff levels were associated with heart failure and poor survival, but the latter seems more obvious.